Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Kabuki syndrome: a Chinese case series and systematic review of the spectrum of mutations

BMC Medical Genetics201516:26

https://doi.org/10.1186/s12881-015-0171-4

Received: 1 November 2014

Accepted: 30 March 2015

Published: 21 April 2015

Abstract

Background

Kabuki syndrome is a rare hereditary disease affecting multiple organs. The causative genes identified to date are KMT2D and KDMA6. The aim of this study is to evaluate the clinical manifestations and the spectrum of mutations of KMT2D.

Methods

We retrospectively retrieved a series of eight patients from two hospitals in China and conducted Sanger sequencing for all of the patients and their parents if available. We also reviewed the literature and plotted the mutation spectrum of KMT2D.

Results

The patients generally presented with typical clinical manifestations as previously reported in other countries. Uncommon symptoms included spinal bifida and Dandy-Walker malformation. With respect to the mutations, five mutations were found in five patients, including two frameshift indels, one nonsense mutation and two missense mutations.

Conclusions

This is the first case series on Kabuki syndrome in Mainland China. Unusual symptoms, such as spinal bifida and Dandy-Walker syndrome, suggested that neurological developmental defects may accompany Kabuki syndrome. This case series helps broaden the mutation spectrum of Kabuki syndrome and adds information regarding the manifestations of Kabuki syndrome.

Keywords

Kabuki syndrome KMT2D Chinese Series Dandy-Walker syndrome Spinal bifida

Background

Kabuki syndrome or Kabuki make-up syndrome was originally described in 1981 following observations of five Japanese children whose conditions were characterized by mental retardation, dwarfism and peculiar faces and abnormal dermatoglyphics [1]. Historically, the diagnostic criteria for Kabuki syndrome were mainly based on the typical clinical manifestations, which were established by analyzing a group of sixty-two patients with Kabuki syndrome in 1988 [2]. Five cardinal manifestations were frequently observed in patients with Kabuki syndrome and could be used as diagnostic clues, including peculiar facial appearances, mild-to-moderate mental retardation, dermatoglyphic abnormalities, skeletal anomalies, and postnatal growth deficiencies. Kabuki syndrome was previously considered to be prevalent in only Japan, but it has now been recognized to be prevalent all over the world. The estimated prevalence in Japan is approximately 1/32,000, whereas the estimated prevalence is at least 1/86,000 in Australia and New Zealand [2,3].

The underlying genetic mutation of Kabuki syndrome was not revealed until the year 2010, when exome sequencing identified MLL2 mutations in Kabuki syndrome patients (Kabuki syndrome 1, OMIM 147920) [4]. Bögershausen et al proposed a new nomenclature for the MLL2 gene as KMT2D [5]. KMT2D consists of fifty-four coding regions and functions as a histone-lysine N-methyltransferase in various signalling pathways such as epigenetic modulating. However, KMT2D mutations alone were not able to account for all Kabuki syndrome cases. Later, mutations in the KDM6A gene, which encodes a histone demethylase that interacts with KMT2D, were identified (Kabuki syndrome 2, OMIM 300867) [6]. Therefore, analyzing mutations in the KMT2D and KDM6A genes would help confirm the diagnosis in patients who fulfilled the clinical diagnostic criteria for Kabuki syndrome.

Medical centres and institutions in Europe, North America and South America have carried out extensive KMT2D mutation spectrum reports. However, studies concerning the KMT2D mutation spectrum in China have rarely been reported. This study describes the first case series of eight Chinese patients with Kabuki syndrome, their clinical manifestations, and their atypical symptoms. We also analyzed the genetic changes in the KMT2D gene and conducted a literature review of the KMT2D mutation spectrum. The main aim of this study was to determine the mutation spectrum of the KMT2D gene in Chinese Kabuki patients and to review the mutation spectrum reported in the literature.

Methods

Patients

This study was reviewed and approved by the Peking Union Medical Collage Hospital Ethics Review Board. All of the participants’ legal guardians provided their written informed consents to participate on behalf of the children and/or for themselves. We obtained written informed consent to publish characteristic features of the disease and to maximally hide other non-disease-related features, thus protecting the privacy for each patient.

We retrospectively searched the clinical records for the initial outpatient visit covering from January 2010 to February 2013 in the Department of Pediatrics, Peking Union Medical College Hospital (PUMCH), Beijing, China and Children’s Hospital of ChongQing Medical University (CH-CQMU), ChongQing, China. Those patients with a clinical diagnosis of “Kabuki syndrome” were enrolled. Overall, eight patients were enrolled. Clinical manifestations were retrieved from the original clinical records. A telephone-based follow-up was conducted to ask for patients’ current height and weight as of February 2013.

Sanger sequencing of KMT2D gene and identification of pathogenic mutations

KMT2D gene mutation status was obtained by Sanger sequencing after obtaining informed consent. First, peripheral blood samples from each patient were collected. Blood samples from the parents were also collected if available. Then, the total genomic DNA was extracted by standard procedures, and the 54 exons and exon-intron junctions of the KMT2D gene (UCSC NM_003482) were amplified in three PCR fragments. Exons were amplified in a reaction containing 2 μL of 10x PCR buffer, 3 μL of dNTPs (2.5 mmol/L), 0.3 μL of rTaq polymerase (5 U/μL) (TAKARA, Dalian, China), 1 μL of genomic DNA (100 ng/μL), 1 μL of each primer (10 pmol/μL), and 11.7 μL of ddH2O. The thermal cycler conditions were as follows: 95°C for 5 min, then 35 cycles of 94°C for 30 s, 59°C for 30 s, and 72°C for 45 s, and a final elongation step at 72°C for 5 min. Direct sequencing was performed on a Genetic Analyzer (Biomed Corp, Beijing, China). As a reference, the A of the ATG translation initiation codon of coding sequence of KMT2D was referred to as nucleotide +1.

Results from Sanger sequencing were compared with the reference sequence of KMT2D to identify single nucleotide substitutions, frameshift indels, and non-frameshift indels. Novel missense mutations would be subjected to further analysis to explore their pathogenicity. First, the parents’ KMT2D genes were sequenced. Second, the proband’s missense mutation was searched in the 1000 Genomes Database and in the Exome Variant Server [7]. Finally, the pathogenicity of protein change due to the missense mutation was predicted using the in silico prediction models SIFT, PROVEAN and Polyphen-2 [8,9].

Literature review of the KMT2D gene mutation spectrum

Two of the authors (CS and XH) independently searched the published literature in MEDLINE and EMBASE using the following search keys: (“Kabuki syndrome” OR “Kabuki make-up syndrome” OR “Niikawa-Kuroki syndrome”) AND (“KMT2D” OR “MLL2”), without language restriction, with published data up to January 6, 2015. Another author (ZQ) supervised the literature review process and resolved any disagreement between the authors (CS and XH) regarding a study’s inclusion. Articles were manually reviewed, and KMT2D mutation data were retrieved. Here, we included only studies with 10 or more patients. The KMT2D mutations were summarized and categorized as “missense,” “frameshift indel” or “nonsense.”

Results

Clinical manifestations of eight Chinese patients with Kabuki syndrome

We identified eight patients with a clinical diagnosis of Kabuki syndrome (six from PUMCH and two from CH-CQMU). Six patients were male, and two were female. The ages of initial diagnosis ranged from 8 months to 9 years. All of patients belonged to the Han ethnic group.

The general clinical manifestations were categorized in a “five cardinal manifestations” pattern, which included typical craniofacial abnormalities, skeletal abnormalities, dermatoglyphic abnormalities, cerebral abnormalities, and postnatal growth deficiencies (Table 1). The percentages of patients with each symptom were compared with previous reports [10]. The typical features of the aforementioned patients are illustrated in Figure 1.
Table 1

Clinical manifestations of eight patients with Kabuki syndrome

Clinical manifestation

Patient 1

Patient 2

Patient 3

Patient 4

Patient 5

Patient 6

Patient 7

Patient 8

Percentage in this series

Cumulative percentage

General Information

Gender

M

M

F

M

F

M

M

M

  

Age of diagnosis

7 y

3 y

8 y

8 mo

2 y

9 y

4 y 11 m

4 y 1 m

  

Age at follow-up

8 y

4 y

  

3 y

  

5 y 6 m

  

Typical craniofacial abnormality

High/sparse eyebrows

+

+

+

+

+

+

+

+

100.0%

85%

Long palpebral fissures

+

+

+

+

+

+

+

+

100.0%

99%

Blue sclera

-

+

+

+

+

 

-

+

71.4%

31%

Strabismus

-

-

-

-

-

-

+

-

12.5%

36%

Ptosis

-

-

-

-

-

-

-

-

0.0%

50%

Large ears

+

+

+

+

+

+

+

+

100.0%

84%

Depressed nasal tip

+

+

+

+

+

+

+

+

100.0%

83%

Micrognathia

-

+

-

+

  

+

+

66.7%

40%

Abnormal dentition

-

-

+

    

+

50.0%

68%

skeletal abnormality

Clinodactyly of the 5th finger

+

+

-

+

-

-

-

+

50.0%

50%

Hip dislocation

+

-

-

-

-

-

 

-

14.3%

18%

Hyperlaxity

+

-

-

-

-

-

 

+

28.6%

74%

Scoliosis/vertebral malformation

+

-

-

-

-

-

-

-

12.5%

32%

Dermatoglyphic abnormalities

Fingertip pads

+

+

+

+

+

+

+

+

100.0%

89%

Cerebral abnormality

Mental retardation

+

+

+

+

+

+

-

+

87.5%

84%

Hypotonia

-

-

-

-

-

-

-

+

12.5%

68%

Seizures

-

-

+

-

+

-

-

-

25%

17%

Head circumference at initial outpatient diagnosis (cm)

51

46.7

50

42.5

42

49.8

49

46.7

  

Microcephaly

-

-

-

-

+

-

-

+

25%

26%

Postnatal growth

Weight at birth (g)

3250

2500

2650

 

2950

  

2000

  

Body length at birth (cm)

50

 

48

 

49

     

Weight at initial outpatient diagnosis (kg)

26

13

 

7

 

20

14

11

  

Height at initial outpatient diagnosis (cm)

121

101

   

107

99

86

  

Weight at follow-up (kg)

27

15

  

12

     

Height at follow-up (cm)

125

102

  

96

  

98

  

Postnatal growth retardation

-

-

  

-

+

+

-

33.3%

55%

Feeding difficulties

+

-

-

-

-

-

-

-

12.5%

 

Other common symptoms

Frequent infections

+

+

-

-

+

-

+

+

62.5%

60%

Cardiac anomalies

-

-

-

-

+

-

+

+

37.5%

42%

Special features

+

+

        
Figure 1

Typical patient abnormalitie. (A) High/sparse eyebrows by Patient 2. (B) High/sparse eyebrows demonstrated by Patient 3. (C) Depressed nasal tip demonstrated by Patient 5. (D) Depressed nasal tip demonstrated by Patient 8. (E) Hyperlaxity demonstrated by Patient 8. (F) Fingertip pads demonstrated by Patient 8.

All of the patients in this case series presented with typical craniofacial abnormalities, including high/sparse eyebrows, long palpebral fissures with eversion of the lateral third of the lower eyelids, large ears and depressed nasal tips and blue sclera. The percentages of patients presenting with strabismus and ptosis were lower than in previous reports.

With respect to skeletal abnormalities, four patients presented with clinodactyly of the 5th finger. Patient 1 was diagnosed with bilateral hip dislocation at one year of age and underwent corrective surgery. The same patient also presented with hyperlaxity and spina bifida occulta. Patient 8 also presented with hyperlaxity.

All of the patients presented with fingertip pads typical of previously reported dermatoglyphic abnormalities. With respect to cerebral abnormalities, seven out of the eight patients presented with mental retardation. Only Patient 5 and Patient 8 presented with microcephaly (two standard deviations from the median value) according to the standard for Chinese children [11]. With respect to seizures, Patient 5 and Patient 3 exhibited this manifestation. Patient 5 presented with an episode of seizure that occurred in the first day of life and was infantile spasm type. MRI indicated corpus callosum hypoplasia and Dandy-Walker malformation, which indicated that congenital cerebral developmental defects might happen concomitantly with Kabuki syndrome.

With respect to postnatal growth, Patient 6 and Patient 7 were diagnosed with postnatal growth retardation, and Patient 1 experienced self-reported feeding difficulties.

In addition to these five cardinal manifestations, Patient 1 experienced fever or diarrhoea every other week from the age of two to three. Patient 2 experienced multiple upper respiratory symptoms and tonsillitis when he was 3 years old. Patients 5, 7 and 8 experienced frequent respiratory infections. With respect to cardiac abnormalities, Patient 5 was diagnosed with a patent foramen ovale and Patient 7 and Patient 8 presented with atrial septal defects. Patient 2 presented with pectus carinatum, and Patient 3 presented with bilateral knee joint stiffness.

Review of the KMT2D gene mutation spectrum in Kabuki syndrome

We performed a literature review of the published studies on KMT2D gene mutations based upon the method described above. The number of studies from MEDLINE and EMBASE were 48 and 182, respectively. After merging the duplicates, there were 201 published articles. Each abstract was manually read, and data were retrieved if available. The data from the included studies contributed to the further analysis.

Briefly, we included 12 studies for further analysis [4,12-22] to compare the distribution of the previously reported KMT2D gene mutations with our case series. We first summarized the different types of mutations from these studies.

There were 146 (47%) frameshift indels, 105 (34%) nonsense mutations, and 56 (18%) pathogenic missense mutations (Figure 2). We did not include splice-site and in-frame indels because the pathogenicity of these mutations would require specific investigation. Mutation hotspots were identified in exons 10, 31, 34, 39, and 48.
Figure 2

Mutation spectrum of the KMT2D gene. (A) Schematic view of the KMT2D gene. Each note above represents a variant in this case series (a red note indicates a pathogenic mutation). Each type of mutation is illustrated as a dot with a distinct combination of colour and shape. Each dot below represents a genetic mutation reported in the literature. (B) Schematic view of the number and proportion of missense, nonsense and in-frame indel mutations in the KMT2D gene.

Sanger sequencing to identify mutations in the KMT2D gene in this study

Our eight patients underwent genetic analysis of the KMT2D gene, and ten variants were detected (Table 2). Unlike the distribution in previous reports, only two frameshift indels and one nonsense mutation were identified, which were c.3095delT in Patient 4, c.4395dupC in Patient 6 and c.4140T > A in Patient 8. One in-frame indel, c.11718-11723delGCAACA, was also identified in Patient 8. Six missense variants were also identified. Patient 1 had two missense variants, c.12199C > T and c.16295G > A (Figure 3). Patients 2, 3, 5 and 7 had one missense variant each: c.4664C > T, c.8639T > C, c.96C > G (p.Asp32Glu) and c.11638C > A, respectively. We sequenced both of the parents of Patients 1, 2, 3 and 5 and found none of the previously described missense variants in the parents’ KMT2D genes. The other four patients’ parents were not available for genetic testing.
Table 2

KMT2D gene variants analysis

Patient

Mutation

Type of mutation

Predicted protein changes

Inheritance

Exon

PROVEAN prediction

SIFT prediction

Polyphen-2 prediction

Pathogenicity

Novelty

      

Score

Prediction*

Score

Prediction**

Score

Prediction

  

Patient 1

c.12199C > T

Missense

p.Pro4067Ser

De novo

39

−1.663

Neutral

0

Damaging

0.085

Benign

Undetermined

Novel

 

c.16295G > A

Missense

p.Arg5432Gln

De novo

51

−3.695

Deleterious

0

Damaging

1.000

Probably damaging

Confirmed

Kokitsu-Nakata et al

Patient 2

c.4664C > T

Missense

p.Ser1555Phe

De novo

17

−0.958

Neutral

0.682

Tolerated

0.976

Probably damaging

Undetermined

Novel

Patient 3

c.8639T > C

Missense

p.Leu2880Pro

De novo

34

−5.055

Deleterious

0

Damaging

1.000

Probably damaging

Confirmed

Novel

Patient 4

c.3095delT

Frameshift indel

p.Leu1032Argfs24X

N/A

11

      

Confirmed

Novel

Patient 5

c.96C > G

Missense

p.Asp32Glu

De novo

2

0.423

Neutral

0.106

Tolerated

0.001

Benign

Undetermined

Novel

Patient 6

c.4395dupC

Frameshift indel

p.Lys1466Glnfs25X

N/A

15

      

Confirmed

Novel

Patient 7

c.11638C > A

Missense

p.Leu3880Met

N/A

39

0.500

Neutral

0.008

Damaging

0.003

Benign

Undetermined

Novel

Patient 8

c.4140T > A

Nonsense

p.Cys1370X

N/A

14

      

Confirmed

Novel

 

c.11718-11723delGCAACA

Non-frameshift indel

p3907-3909delQQ

N/A

39

−1.298

Neutral

    

Undetermined

Novel

*Cutoff = -2.5.

**Cutoff = 0.05f.

Figure 3

Sanger sequencing of Patient 1 with two de novo mutations. (A) The missense mutation c.12199C > T in Patient 1. (B, C) Both parents had no mutations at c.12199. (D) The missense mutation c.16295G > A in Patient 1. (E, F) Both parents had no mutation at c. 16295.

We did not find any of the missense variants identified in this series in the 1000 Genomes Database or the Exome Variant Server.

With respect to the pathogenicity analysis, we used the in silico prediction models SIFT, PROVEAN and Polyphen-2 to predict the protein changes due to the missense variants. Two missense variants (c.16295G > A and c.8639T > C) were predicted to be pathogenic by all three of the models. Therefore, we categorized those two variants as “pathogenicity confirmed.” However, the other four missense variants (c.12199C > T, c.4664C > T, c.96C > G and c.11638C > A) were predicted to be benign, neutral or tolerable by at least two of the programs. Therefore, we would categorize those four variants as “pathogenicity undetermined.” The single in-frame indel in Patient 8 (c.11718-11723delGCAACA) was also categorized as “pathogenicity undetermined.”

In conclusion, five of the eight patients had pathogenic mutations in the KMT2D gene. These patients were Patient 1 (c.16295G > A), Patient 3 (c.8639T > C), Patient 4 (c.3095delT), Patient 6 (c.4395dupC), and Patient 8 (c.4140T > A). Three of the eight patients did not have confirmatory pathogenic mutations in the KMT2D gene, and the clinical symptoms could not be ascribed to KMT2D gene mutations. These patients were Patient 2, Patient 5, and Patient 7.

Nine of the ten variants were novel. One missense variant (c.16295G > A) was previously reported by Kokitsu-Nakata et al [23].

Discussion

Kabuki syndrome is a rare congenital disease. Cases from different parts of the world have been extensively reported. However, reports on Chinese patients with Kabuki syndrome have been rare. To our knowledge, five cases of Chinese patients due to this disease were published in several case reports [24-27]. However, the KMT2D mutation status was not available for these cases. This is the first case series to include both the typical clinical manifestations and the KMT2D mutation status of patients from Mainland China. The clinical manifestations in this case series were consistent with the clinical diagnostic criteria.

With respect to atypical symptoms, Patient 5 presented with hypoplasia of the corpus callosum and Dandy-Walker malformation. Increasing evidence suggests that structural central nervous system (CNS) malformations, including Dandy-Walker malformation, can be present in Kabuki syndrome patients [28-31]. These congenital neurologic defects may partially account for the mental retardation commonly observed in Kabuki syndrome patients. Further analysis is needed to evaluate whether CNS structural defect are frequent in patients with Kabuki syndrome.

With respect to congenital heart defects, the major types associated with Kabuki syndrome are left-sided obstructions and aortic dilation, coarctation of the aorta (COA), atrial septal defects (ASDs), ventral septal defects (VSDs), and tetralogy of Fallot (TOF), among others [32,33]. In our series, two patients presented with ASDs. Thus, we propose that patients should be meticulously screened for congenital heart defects once the diagnosis of Kabuki syndrome has been made.

Gene sequencing of KMT2D and KDM6A can be used to detect mutations in patients with a clinical diagnosis of Kabuki syndrome. Studies with large cohorts of patients indicate that KMT2D gene mutations can be detected in half to three-fourths of patients with clinical diagnoses of Kabuki syndrome [13,16,17]. Pathogenic KDM6A gene mutations account for a small percentage of patients [14,16,19,34-36].

KMT2D pathogenic mutations were detected in five of the eight patients in our case series. This case series identified six missense variants, two frameshift indels, one in-frame indel and one nonsense mutation. All of the frameshift indels and nonsense mutations were considered pathogenic because the protein structure was significantly altered. However, we would urge caution in interpreting the influence of missense mutations or in-frame indels on protein function because some amino acid substitutions would not necessarily impair protein function. Therefore, we used in silico prediction models to analyze the missense mutations and non-frameshift indels.

We found two patients with two variants in their KMT2D genes. Patient 1 had two missense mutations (c.12199C > T and c.16295G > A), which were both absent from the parents’ KMT2D genes, indicating that they were de novo mutations. Both mutations were absent from the 1000 Genomes Database and the Exome Variant Server, indicating that both mutations are rare in the general population. One mutation, c.12199C > T, was predicted to be pathogenic by the SIFT program but not by PROVEAN or Polyphen-2. The other mutation, c.16295G > A, was predicted to be pathogenic by all three in silico models and has been reported by Kokitsu-Nakata et al in a Brazilian case of familial Kabuki syndrome [23]. Therefore, we considered c.16295G > A to be pathogenic, whereas the pathogenicity of c.12199C > T was inconclusive and could potentially be non-pathogenic.

Patient 8 also had two variants. We could not determine the inheritance status because the parents of Patient 8 refused to give blood samples for sequencing of the KMT2D gene. One mutation was a nonsense mutation (c.4140T > A), which was considered to be pathogenic. The other mutation in this patient was an in-frame deletion (c.11718-11723delGCAACA), which was predicted to be non-pathogenic by the PROVEAN prediction model. Therefore, the pathogenicity of c.11718-11723delGCAACA was inconclusive and could potentially be non-pathogenic. To our knowledge, it is a rare event for a patient to carry two mutant variants of the KMT2D gene. A previous study by Hannibal et al reported only three patients who carried two KMT2D gene variants in a cohort of 110 patients [22].

Conclusion

This report is the first case series of Kabuki syndrome patients with definitive genetic diagnosis in China. These data help broaden the mutation spectrum of Kabuki syndrome and add information regarding the manifestations of Kabuki syndrome.

Declarations

Funding

The present study was funded by the National Science & Technology Pillar Program during the Twelfth Five-year Plan Period (No. 2012BAI09B00).

Authors’ Affiliations

(1)
Department of Pediatrics, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
(2)
Peking Union Medical College
(3)
BGI research
(4)
Endocrinology Department, Children’s hospital of ChongQing Medical University

References

  1. Niikawa N, Matsuura N, Fukushima Y, Ohsawa T, Kajii T. Kabuki make-up syndrome: a syndrome of mental retardation, unusual facies, large and protruding ears, and postnatal growth deficiency. J Pediatr. 1981;99(4):565–9.PubMedGoogle Scholar
  2. Niikawa N, Kuroki Y, Kajii T, Matsuura N, Ishikiriyama S, Tonoki H, et al. Kabuki make-up (Niikawa-Kuroki) syndrome: a study of 62 patients. Am J Med Genet. 1988;31(3):565–89.PubMedGoogle Scholar
  3. White SM, Thompson EM, Kidd A, Savarirayan R, Turner A, Amor D, et al. Growth, behavior, and clinical findings in 27 patients with Kabuki (Niikawa-Kuroki) syndrome. Am J Med Genet A. 2004;127a(2):118–27.PubMedGoogle Scholar
  4. Ng SB, Bigham AW, Buckingham KJ, Hannibal MC, McMillin MJ, Gildersleeve HI, et al. Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nat Genet. 2010;42(9):790–3.PubMedPubMed CentralGoogle Scholar
  5. Bogershausen N, Bruford E, Wollnik B. Skirting the pitfalls: a clear-cut nomenclature for H3K4 methyltransferases. Clin Genet. 2013;83(3):212–4.PubMedGoogle Scholar
  6. Lederer D, Grisart B, Digilio MC, Benoit V, Crespin M, Ghariani SC, et al. Deletion of KDM6A, a histone demethylase interacting with MLL2, in three patients with Kabuki syndrome. Am J Hum Genet. 2012;90(1):119–24.PubMedPubMed CentralGoogle Scholar
  7. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56–65.PubMedGoogle Scholar
  8. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels. PLoS One. 2012;7(10), e46688.PubMedPubMed CentralGoogle Scholar
  9. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248–9.PubMedPubMed CentralGoogle Scholar
  10. Huh JK, Chung MS, Baek GH, Oh JH, Lee YH, Gong HS. Cleft hand in Kabuki make-up syndrome: case report. J Hand Surg [Am]. 2011;36(4):653–7.Google Scholar
  11. Li H. Growth standardized values and curves based on weight, length/height and head circumference for Chinese children under 7 years of age. Zhonghua Er Ke Za Zhi. 2009;47(3):173–8.PubMedGoogle Scholar
  12. Courcet JB, Faivre L, Michot C, Burguet A, Perez-Martin S, Alix E, et al. Clinical and molecular spectrum of renal malformations in Kabuki syndrome. J Pediatr. 2013;163(3):742–6.PubMedGoogle Scholar
  13. Banka S, Veeramachaneni R, Reardon W, Howard E, Bunstone S, Ragge N, et al. How genetically heterogeneous is Kabuki syndrome?: MLL2 testing in 116 patients, review and analyses of mutation and phenotypic spectrum. Eur J Hum Genet. 2012;20(4):381–8.PubMedGoogle Scholar
  14. Cheon CK, Sohn YB, Ko JM, Lee YJ, Song JS, Moon JW, et al. Identification of KMT2D and KDM6A mutations by exome sequencing in Korean patients with Kabuki syndrome. J Hum Genet. 2014;59(6):321–5.PubMedGoogle Scholar
  15. Dentici ML, Di Pede A, Lepri FR, Gnazzo M, Lombardi MH, Auriti C, et al. Kabuki syndrome: clinical and molecular diagnosis in the first year of life. Arch Dis Child. 2014;100(2):158–64.PubMedGoogle Scholar
  16. Miyake N, Koshimizu E, Okamoto N, Mizuno S, Ogata T, Nagai T, et al. MLL2 and KDM6A mutations in patients with Kabuki syndrome. Am J Med Genet A. 2013;161a(9):2234–43.PubMedGoogle Scholar
  17. Makrythanasis P, van Bon BW, Steehouwer M, Rodriguez-Santiago B, Simpson M, Dias P, et al. MLL2 mutation detection in 86 patients with Kabuki syndrome: a genotype-phenotype study. Clin Genet. 2013;84(6):539–45.PubMedGoogle Scholar
  18. Paulussen AD, Stegmann AP, Blok MJ, Tserpelis D, Posma-Velter C, Detisch Y, et al. MLL2 mutation spectrum in 45 patients with Kabuki syndrome. Hum Mutat. 2011;32(2):E2018–25.PubMedGoogle Scholar
  19. Micale L, Augello B, Maffeo C, Selicorni A, Zucchetti F, Fusco C, et al. Molecular analysis, pathogenic mechanisms, and readthrough therapy on a large cohort of Kabuki syndrome patients. Hum Mutat. 2014;35(7):841–50.PubMedPubMed CentralGoogle Scholar
  20. Li Y, Bogershausen N, Alanay Y, Simsek Kiper PO, Plume N, Keupp K, et al. A mutation screen in patients with Kabuki syndrome. Hum Genet. 2011;130(6):715–24.PubMedGoogle Scholar
  21. Micale L, Augello B, Fusco C, Selicorni A, Loviglio MN, Silengo MC, et al. Mutation spectrum of MLL2 in a cohort of Kabuki syndrome patients. Orphanet J Rare Dis. 2011;6:38.PubMedPubMed CentralGoogle Scholar
  22. Hannibal MC, Buckingham KJ, Ng SB, Ming JE, Beck AE, McMillin MJ, et al. Spectrum of MLL2 (ALR) mutations in 110 cases of Kabuki syndrome. Am J Med Genet A. 2011;155a(7):1511–6.PubMedGoogle Scholar
  23. Kokitsu-Nakata NM, Petrin AL, Heard JP, Vendramini-Pittoli S, Henkle LE, dos Santos DV, et al. Analysis of MLL2 gene in the first Brazilian family with Kabuki syndrome. Am J Med Genet A. 2012;158a(8):2003–8.PubMedGoogle Scholar
  24. Yang XJ, Zeng Y, Xiong F. Kabuki syndrome case report. Zhonghua Er Ke Za Zhi. 2010;48(11):868–70.PubMedGoogle Scholar
  25. Atar M, Lee W, O’Donnell D. Kabuki syndrome: oral and general features seen in a 2-year-old Chinese boy. Int J Paediatr Dent. 2006;16(3):222–6.PubMedGoogle Scholar
  26. Ma KH, Chow SN, Yau FT. Isolated adrenocorticotropin deficiency in a child with Kabuki syndrome. J Pediatr Endocrinol Metab. 2005;18(6):607–9.PubMedGoogle Scholar
  27. Wang LC, Chiu IS, Wang PJ, Wu MH, Wang JK, Hung YB, et al. Kabuki make-up syndrome associated with congenital heart disease. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1994;35(1):63–9.PubMedGoogle Scholar
  28. Chu DC, Finley SC, Young DW, Proud VK. CNS malformation in a child with Kabuki (Niikawa-Kuroki) syndrome: report and review. Am J Med Genet. 1997;72(2):205–9.PubMedGoogle Scholar
  29. Ben-Omran T, Teebi AS. Structural central nervous system (CNS) anomalies in Kabuki syndrome. Am J Med Genet A. 2005;137(1):100–3.PubMedGoogle Scholar
  30. Topcu Y, Bayram E, Karaoglu P, Yis U, Kurul SH. Kabuki syndrome and perisylvian cortical dysplasia in a Turkish girl. J Pediatr Neurosci. 2013;8(3):259–60.PubMedPubMed CentralGoogle Scholar
  31. Yoshioka S, Takano T, Matsuwake K, Sokoda T, Takeuchi Y. A Japanese patient with Kabuki syndrome and unilateral perisylvian cortical dysplasia. Brain Dev. 2011;33(2):174–6.PubMedGoogle Scholar
  32. Yuan SM. Congenital heart defects in Kabuki syndrome. Cardiol J. 2013;20(2):121–4.PubMedGoogle Scholar
  33. Digilio MC, Marino B, Toscano A, Giannotti A, Dallapiccola B. Congenital heart defects in Kabuki syndrome. Am J Med Genet. 2001;100(4):269–74.PubMedGoogle Scholar
  34. Banka S, Lederer D, Benoit V, Jenkins E, Howard E, Bunstone S, et al. Novel KDM6A (UTX) mutations and a clinical and molecular review of the X-linked Kabuki syndrome (KS2). Clin Genet. 2014;87(3):252–8.PubMedGoogle Scholar
  35. Lindgren AM, Hoyos T, Talkowski ME, Hanscom C, Blumenthal I, Chiang C, et al. Haploinsufficiency of KDM6A is associated with severe psychomotor retardation, global growth restriction, seizures and cleft palate. Hum Genet. 2013;132(5):537–52.PubMedPubMed CentralGoogle Scholar
  36. Lederer D, Shears D, Benoit V, Verellen-Dumoulin C, Maystadt I. A three generation X-linked family with Kabuki syndrome phenotype and a frameshift mutation in KDM6A. Am J Med Genet A. 2014;164a(5):1289–92.PubMedGoogle Scholar

Copyright

© Liu et al.; licensee BioMed Central. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement